Eikonizo Therapeutics
@Eikonizo
Followers
130
Following
43
Media
28
Statuses
73
Envisioning an end to neurodegenerative and other diseases
CIC, Cambridge MA
Joined July 2019
#TBT! On 10/17 we presented at the @ALSTDI Summit on the evolution of HDAC6 as a potential tx target for ALS and the value of collaborative data and resource sharing to advance ALS research. Watch both videos here: https://t.co/U6Q6ibHTdp
https://t.co/mnVLOBhL5L
@flyneurogirl
0
1
1
Exciting progress ahead! Our team, in collaboration with @CedarsSinai Medical Center, will present new preclinical data at @AHAScience #AHA2025 showcasing Eikonizo’s novel #HDAC6 inhibitors as a new #Cardiometabolic approach for #HFpEF. Find us 11/8 at 2:30pm CT (LBBS.APS.01)
0
0
0
Our CEO @RickLundberg is looking forward to joining other biopharma CEOs at the Boston CEO conference Oct 27-28 in Boston. If you’re attending, check out his panel presentation on the Ecosystem of Innovation.
0
0
1
Great summary in @alsnewstoday on @Eikonizo selective HDAC6 inhibitors & EKZ-102 for #NeurodegenerativeDisease including #ALS. Check out the full research underlying these findings in @Brain1878:
academic.oup.com
HDAC6 inhibitors are promising therapeutic candidates for neurodegenerative disorders, but previous compounds have lacked adequate selectivity and CNS pene
New ALS Drug in Development: https://t.co/zo40sDiVF5
@Eikonizo experimental oral therapy, EKZ-102, is expected to begin clinical testing in 2026. In mouse models, the treatment eased disease severity by targeting a protein called HDAC6, which helps cells clear out toxic protein
0
0
1
Our panel of ALS research leaders takes the stage to discuss the power of collaboration and data sharing to accelerate discoveries. #ALSTDISummit 🎤: Fernando Vieira, MD, @ALSTDI; Tonya Gilbert, PhD, @Eikonizo; Irina Antonijevic, MD, PhD, @TraceNeuro; Tris Dyson, @ChallengeWorks
0
2
7
Our team will present preclinical ALS research and join an #ALS panel at the 2025 @ALSTDI Summit, advancing our mission to develop disease-modifying therapies. Info: https://t.co/gCEHX0jr10
#ALS #Neurodegeneration #Biotech
als.net
Register to attend the ALS TDI Summit on October 17th! Join us virtually or in-person to hear updates on the latest progress in ALS research.
0
1
3
@brain Sorry, correct Brain publication handle is @brain1878!
0
0
0
@brain In addition, we recently received a SBIR grant to advance our lead product candidate, EKZ-102, in #ParkinsonsDisease, further expanding our efforts to address multiple devastating neurodegenerative conditions. Read our press release:
businesswire.com
Eikonizo Therapeutics, a biopharmaceutical company developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and ca...
1
0
2
Our latest research has been advance published online in @Brain, highlighting the neurodegenerative disease-modifying potential of our selective HDAC6 inhibitors in preclinical #ALS and #FTD models. Read more:
academic.oup.com
HDAC6 inhibitors are promising therapeutic candidates for neurodegenerative disorders, but previous compounds have lacked adequate selectivity and CNS pene
4
0
2
We’re pleased to share two important milestones in our mission to change the course of neurodegenerative disease.
1
0
2
Sunday was #WorldAlzheimersDay — a global effort to raise awareness and challenge stigmas around Alzheimer’s disease & other dementias. At Eikonizo we're developing disease-modifying therapeutics to improve the lives of people impacted by neurodegenerative disease, including AD.
0
0
1
Excited to have our CEO @RickLundberg attend #BIO2025 this week — connecting with fellow innovators and potential partners shaping the future of biotech. If you’re in Boston and want to talk science, strategy, or collaboration, let’s connect! #LifeSciences #Innovation
0
0
2
Eikonizo’s CSO Richard Fisher was honored to present our findings in his presentation "Development of EKZ-102, a CNS-Penetrant Small Molecule HDAC6 Inhibitor as a Potential first-in-class Disease Modifying Therapeutic for ALS" at the ALS Drug Development Summit today in Boston.
0
0
0
It's Friday and Day 2 of the Convergence Forum in beautiful Chatham, MA! Our CEO @RickLundberg is on site meeting with industry leaders and future collaborators. Learn more about Eikonizo's science and programs here: https://t.co/y51GEpEXHc
0
0
0
This week through May 11 are #HeartFailureAwarenessDays Eikonizo’s HDAC6 inhibitor platform has the potential to address intracellular transport and proteostasis, two key drivers of cardiorenal disease and heart failure. https://t.co/JWDYy8mldR
@escardio #HFA_ESC
0
0
1
@Eikonizo Clinical Advisor Angela Genge @genge_angela, Director of the ALS Center at @mcgillu, presented an overview of current #ALS clinical trials and innovative therapeutics today at #ADPD2025 in #Vienna.
linkedin.com
I am honored to speak and chair the afternoon session at AD/PD 2025 today on new developments in biomarkers and clinical trials in ALS, Alzheimer’s and neurodegeneration. #ADPD2025
0
0
1
Work hard, play hard! @Eikonizo prides itself on being a team-oriented and fun place to work, as these pics from our recent social gaming outing at #Level99 can attest. #TeamBuilding #WorkHardPlayHard
0
1
3
Today is #NationalWearRedDay established by @American_Heart to raise awareness of #CardiovasularDisease – the #1 killer of women. DYK, according to @ACC women are at higher risk of #HFpEF, a type of heart failure with limited effective treatment options, than men? @GoRedForWomen
0
1
1
Our CSO Richard Fisher was on site at the 15th annual California #ALS Research Summit in SF last week. Sponsored by the ALS Network, this annual event provides an opportunity for experts in the field to share the latest advancements in #ALSresearch. #HDAC6inhibitor
0
0
1
The @Eikonizo team was out and about in SF for the @jpmorgan Healthcare Conference. Hope you gave @RickLundberg and team a wave if you saw them trekking around Union Sq! #JPMorgan #HDAC6inhibitor
0
0
1